kabutan

Daito Pharma, First Half Ordinary Profit Decreases by 36%, Sep-Nov Ordinary Profit Decreases by 60%

Fri Jan 10, 2025 3:30 pm JST Earnings

4577 Daito Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

Daito Pharmaceutical Co.,Ltd. <4577> [TSE Prime] announced its financial results after the market closed on January 10th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending May 2025 (June to November) dropped 36.5% from the same period last year to 1.47 billion yen. The progress rate toward the full-year plan of 3.5 billion yen was 42.0%, also falling below the five-year average of 56.5%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the December to May period (2H) is expected to grow 26.2% from the same period last year, reaching 2.03 billion yen.

In the most recent three-month period, from September to November (2Q), the consolidated ordinary profit significantly dropped to 0.48 billion yen, a 60.1% decrease compared to the same period last year. The operating profit margin significantly dropped from 10.1% in the same period last year to 5.2%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jun - Nov, 2022 23,367 2,826 2,752 1,762 55.7 53.2 Jan 13, 2023 J-GAAP
Jun - Nov, 2023 24,110 2,289 2,314 1,552 49.1 59.0 Jan 12, 2024 J-GAAP
Jun - Nov, 2024 24,584 1,471 1,470 908 29.7 42.0 Jan 10, 2025 J-GAAP
YoY +2.0% -35.7% -36.5% -41.5% -39.5%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jun - Nov, 2024 Guidance ー ー ー ー － 17.50 Jul 12, 2024 J-GAAP
Jun - Nov, 2024 Results 24,584 1,471 1,470 908 29.7 17.50 Jan 10, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec - May, 2023 22,785 1,605 1,609 1,743 55.5 15 Jul 12, 2024 J-GAAP
Dec - May, 2024 Guidance 24,416 2,029 2,030 1,392 46.4 17.50 Jan 10, 2025 J-GAAP
YoY +7.2% +26.4% +26.2% -20.1% -16.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
May, 2023 45,101 5,207 5,169 3,600 113.8 27.27 Jul 14, 2023 J-GAAP
May, 2024 46,895 3,894 3,923 3,295 105.0 30 Jul 12, 2024 J-GAAP
May, 2025 Guidance 49,000 3,500 3,500 2,300 76.7 35 Jul 12, 2024 J-GAAP
YoY +4.5% -10.1% -10.8% -30.2% -27.0%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Sep - Nov, 2023 11,932 1,209 1,222 869 27.5 10.1 Jan 12, 2024 J-GAAP
Dec - Feb, 2023 10,552 816 808 787 25.0 7.7 Apr 12, 2024 J-GAAP
Mar - May, 2024 12,233 789 801 956 30.5 6.4 Jul 12, 2024 J-GAAP
Jun - Aug, 2024 12,678 849 983 618 20.2 6.7 Oct 11, 2024 J-GAAP
Sep - Nov, 2024 11,906 622 487 290 9.5 5.2 Jan 10, 2025 J-GAAP
YoY -0.2% -48.6% -60.1% -66.6% -65.5%

Related Articles